The risks of HBV infection after liver transplantation from HBc antibody positive donor to HBs antibody positive recipient.
The rate of de novo hepatitis B infection, after liver transplantation from a hepatitis B core antibody (HBcAb) (+) donor to a surface antibody (HBsAb) (+) recipient has not yet elucidated. Four recipients with HBsAb (+) and HBcAb (+), who received living donor grafts from HBcAb (+) donors were herein reviewed. They received lamivudine monotherapy: three patients with HBsAb titer >10 IU/L did not demonstrate the onset of HBsAg, whereas one patient with HBsAb titer <10 IU/L developed hepatitis B antigen (HBsAg) 4 years after transplantation. An HBsAb (+) patient with a titer of >10 IU/L is therefore considered not to require combination therapy when receiving an HBcAb (+) liver graft. However, a great deal of caution is necessary in patients with negative or low HBsAb titers <10 IU/L.
Ikegami
Toru
T
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. tikesurg@yahoo.co.jp
Taketomi
Akinobu
A
Ohta
Ryuji
R
Soejima
Yuji
Y
Yoshizumi
Tomoharu
T
Harada
Noboru
N
Shimada
Mitsuo
M
Maehara
Yoshihiko
Y
D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000635:transmission*; D006512:Hepatitis B Core Antigens / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors
D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens